YmAbs Therapeutics (YMAB)
(Delayed Data from NSDQ)
$14.84 USD
-0.45 (-2.94%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $14.83 -0.01 (-0.07%) 7:56 PM ET
1-Strong Buy of 5 1
F Value D Growth D Momentum F VGM
Income Statements
Fiscal Year end for YmAbs Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 85 | 65 | 35 | 21 | 0 |
Cost Of Goods | 11 | 7 | 2 | 0 | 0 |
Gross Profit | 73 | 58 | 33 | 21 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 99 | 153 | 148 | 141 | 83 |
Income After Depreciation & Amortization | -26 | -95 | -115 | -120 | -83 |
Non-Operating Income | 5 | -1 | 60 | 1 | 2 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -21 | -96 | -55 | -119 | -81 |
Income Taxes | 1 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -21 | -96 | -55 | -119 | -81 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -21 | -96 | -55 | -119 | -81 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -25 | -94 | -115 | -120 | -83 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 1 | 0 | 0 |
Income After Depreciation & Amortization | -26 | -95 | -115 | -120 | -83 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 43.65 | 43.70 | 43.18 | 40.12 | 35.18 |
Diluted EPS Before Non-Recurring Items | -0.49 | -2.19 | -1.28 | -2.97 | -2.30 |
Diluted Net EPS (GAAP) | -0.49 | -2.19 | -1.28 | -2.97 | -2.30 |
Fiscal Year end for YmAbs Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 23.36 | 20.45 | 20.75 | 20.25 |
Cost Of Goods | NA | 2.04 | 2.60 | 4.65 | 2.08 |
Gross Profit | NA | 21.32 | 17.86 | 16.10 | 18.17 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 24.53 | 25.61 | 23.33 | 25.67 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -3.21 | -7.75 | -7.23 | -7.50 |
Non-Operating Income | NA | 2.41 | 0.19 | 1.10 | 1.11 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -0.79 | -7.56 | -6.12 | -6.39 |
Income Taxes | NA | 0.20 | 0.19 | 0.18 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -0.99 | -7.75 | -6.30 | -6.39 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -0.99 | -7.75 | -6.30 | -6.39 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 43.63 | 43.62 | 43.66 | 43.67 |
Diluted EPS Before Non-Recurring Items | NA | -0.02 | -0.18 | -0.14 | -0.15 |
Diluted Net EPS (GAAP) | NA | -0.02 | -0.18 | -0.14 | -0.15 |